Amarin Corporation plc (AMRN)
$11.58+0.43%Close
SELLCRISIS · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $240M
- Beta
- 0.77
- P/E (TTM)
- -8.11
- Short % float
- 2.53%
- Days to cover
- 10.5
- SI change
- +0.5%
- 1W
- -4.06%
- 1M
- -17.29%
- vs SPY 1W
- -3.92%
- vs SPY 1M
- -19.79%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 8
- GROWTH
- 36
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-3.6%
REV YoY-
ROE-6.0%
EPS YoY-
ROA-4.3%
GROSS42
OP-18
NET-15
[VALUATION]
P/E TTM-8.11
P/E FWD-
SECTOR PE20.34
INDUSTRY PE10.09
P/B0.54
P/FCF-
EV/EBITDA-5.14
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.18
ALTMAN Z-
CURR RATIO3.67
ND/EBITDA-
BETA0.77
Company news
FAQ
- What is LOPJLB’s current signal on AMRN?
- LOPJLB’s latest quantitative signal on Amarin Corporation plc (AMRN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AMRN in?
- Amarin Corporation plc (AMRN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Amarin Corporation plc (AMRN) do?
- Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescri…